Company: INKT
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0000950170-25-055881
Chunk: 18

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 18
---
 Ph.D., a strategic consultant to us and Scientific Advisory Board Member and our former Chief Scientific Officer, and Christine M. Klaskin, our Treasurer, who also serves as Vice President, Finance, of Agenus. These individuals are referred to collectively in this proxy statement as our “named executive officers.” Amounts in the tables below do not include any amounts awarded to, earned by, or paid to our named executive officers by Agenus in respect of their employment with or services provided to Agenus.

With respect to the compensation of our named executive officers other than Ms. Klaskin, our Compensation Committee was responsible for determining the compensation of such executive officers during fiscal year 2024. With respect to Ms. Klaskin, who was also an officer of Agenus during 2024, Agenus and the compensation committee of Agenus were responsible for determining her compensation. Our President and Chief Executive Officer also made recommendations with respect to the compensation of her direct reports for fiscal year 2024.

<div align='center'>14</div>

Summary Compensation Table The following table sets forth the compensation awarded to, earned by, or paid to our named executive officers in respect of their service to us for the fiscal years ended December 31, 2024 and 2023:

| Name and Principal Position                                                                |     | Year |      |     | Salary 
 ($)(4) |         |     | Bonus  
 ($)(5) |         |     | Stock  
 Awards 
 ($)(6) |           |     | Option 
 Awards 
 ($)(7) |         |     | All Other    
 Compensation 
 ($)(8)       |        |     | Total 
 ($)   |           |
| Jennifer S. Buell, Ph.D.(1)                                                                |     |      | 2024 |     |        | 448,000 |     |        |       - |     |        |         - |     |        | 345,000 |     |              |  5,686 |     |       |   798,686 |
| President and Chief Executive Officer                                                      |     |      | 2023 |     |        | 451,048 |     |        | 460,000 |     |        | 1,005,694 |     |        | 885,000 |     |              |  5,697 |     |       | 2,807,439 |
| Marc van Dijk, Ph.D. (2)                                                                   |